Vicore Pharma Holding 将来の成長

Future 基準チェック /06

Vicore Pharma Holdingの収益と利益は、それぞれ年間102.5%と29.9%減少すると予測されています。EPS は年間16.1%で減少すると予想されています。自己資本利益率は 3 年後に-58.4%になると予測されています。

主要情報

-29.9%

収益成長率

-16.1%

EPS成長率

Biotechs 収益成長	37.6%
収益成長率	-102.5%
将来の株主資本利益率	-58.4%
アナリストカバレッジ	Low
最終更新日	09 Oct 2024

今後の成長に関する最新情報

Recent updates

業績と収益の成長予測

DB:6Y4 - アナリストの将来予測と過去の財務データ ( )SEK Millions
日付	収益	収益	フリー・キャッシュフロー	営業活動によるキャッシュ	平均アナリスト数
12/31/2026	N/A	-344	-360	-360	3
12/31/2025	N/A	-312	-335	-352	3
12/31/2024	103	-188	-39	-114	3
9/30/2024	104	-196	-181	-181	N/A
6/30/2024	104	-200	-129	-129	N/A
3/31/2024	104	-213	-149	-149	N/A
12/31/2023	N/A	-311	-250	-250	N/A
9/30/2023	N/A	-260	-282	-282	N/A
6/30/2023	N/A	-265	-314	-314	N/A
3/31/2023	N/A	-261	-309	-306	N/A
12/31/2022	N/A	-288	-303	-300	N/A
9/30/2022	N/A	-308	-278	-275	N/A
6/30/2022	N/A	-337	-280	-277	N/A
3/31/2022	N/A	-342	-289	-289	N/A
12/31/2021	N/A	-296	-265	-265	N/A
9/30/2021	N/A	-274	-232	-229	N/A
6/30/2021	N/A	-213	-189	-186	N/A
3/31/2021	N/A	-167	-141	-138	N/A
12/31/2020	N/A	-147	-123	-120	N/A
9/30/2020	N/A	-116	-106	-106	N/A
6/30/2020	N/A	-103	-101	-101	N/A
3/31/2020	N/A	-105	-98	-98	N/A
12/31/2019	N/A	-93	-87	-87	N/A
9/30/2019	0	-79	-90	-88	N/A
6/30/2019	0	-71	-73	-71	N/A
3/31/2019	0	-38	-46	-44	N/A
12/31/2018	1	-22	-35	-33	N/A
9/30/2018	-1	-26	-13	-27	N/A
6/30/2018	0	-12	N/A	-24	N/A
3/31/2018	0	-22	N/A	-32	N/A
12/31/2017	1	-24	N/A	-28	N/A
9/30/2017	3	-8	N/A	-8	N/A
6/30/2017	3	-8	N/A	-7	N/A
3/31/2017	3	-7	N/A	-6	N/A
12/31/2016	1	-25	N/A	-21	N/A
9/30/2016	2	-6	N/A	N/A	N/A
6/30/2016	2	-6	N/A	N/A	N/A
3/31/2016	2	-5	N/A	N/A	N/A
12/31/2015	2	-5	N/A	-4	N/A
9/30/2015	2	7	N/A	N/A	N/A
6/30/2015	1	10	N/A	N/A	N/A
3/31/2015	1	12	N/A	N/A	N/A
12/31/2014	2	14	N/A	-3	N/A
9/30/2014	2	2	N/A	N/A	N/A
6/30/2014	2	0	N/A	N/A	N/A
3/31/2014	3	-1	N/A	N/A	N/A
12/31/2013	3	-2	N/A	-2	N/A

アナリストによる今後の成長予測

収入対貯蓄率: 6Y4今後 3 年間、利益が出ない状態が続くと予測されています。

収益対市場: 6Y4今後 3 年間、利益が出ない状態が続くと予測されています。

高成長収益: 6Y4今後 3 年間、利益が出ない状態が続くと予測されています。

収益対市場: 6Y4の収益は今後 3 年間で減少すると予想されています (年間-102.5% )。

高い収益成長: 6Y4の収益は今後 3 年間で減少すると予測されています (年間-102.5% )。

一株当たり利益成長率予想

将来の株主資本利益率

将来のROE: 6Y4 3 年以内に赤字になると予測されています。

Vicore Pharma Holding 将来の成長

Future 基準チェック /06

主要情報

今後の成長に関する最新情報

No longer forecast to breakeven

No longer forecast to breakeven

Vicore Pharma Holding AB (Publ) Resumes VP02 Production

Recent updates

Vicore Pharma Holding AB (publ) to Report Q2, 2025 Results on Aug 22, 2025

Vicore Pharma Holding AB (publ), Annual General Meeting, May 06, 2025

New major risk - Shareholder dilution

Vicore Pharma Holding AB (publ) has filed a Follow-on Equity Offering in the amount of SEK 782.138028 million.

Vicore Pharma Holding AB Initiates the Global, Randomized Phase 2B Aspre Trial Evaluating the Disease-Modifying Potential of Buloxibutid in Idiopathic Pulmonary Fibrosis

Less than half of directors are independent

Vicore Pharma Holding AB (Publ) Announces Board Appointments

Vicore Pharma Holding AB (Publ) Announces Maarten Kraan, as Board Member Declined Re-Election

Vicore Announces FDA Breakthrough Device Designation for AlmeeTM, a Digital Therapy for Patients with Pulmonary Fibrosis

No longer forecast to breakeven

Vicore Pharma Holding AB (publ) to Report Q4, 2024 Results on Feb 27, 2025

New minor risk - Share price stability

Vicore Pharma Holding AB (publ) Confirms IPF Development Program on Track and Provides Early-Stage Pipeline Updates

Vicore Pharma Holding AB (publ) Appoints Bertil Lindmark as Chief Medical Officer

New minor risk - Share price stability

Vicore Pharma Holding AB (publ) to Report Q2, 2024 Results on Aug 22, 2024

Vicore Pharma Holding AB (publ), Annual General Meeting, May 07, 2024

Vicore Pharma Holding AB (publ) Provides Update Regarding Phase 1 Study of C106

New major risk - Revenue and earnings growth

Vicore Pharma Holding AB (publ) Reports Data from EndoPAT® Exploratory Trial

New major risk - Shareholder dilution

Vicore Pharma Holding AB (Publ) Announces Executive Changes

Vicore Pharma Holding AB (publ) Reports New 36-Week Data from the Air Trial Demonstrating Sustainable Disease Stimulating the Potential of A New Class of Drugs to Stop Disease Propose and Restate in IPF Patients

Vicore Pharma Holding AB (publ) to Report Q2, 2023 Results on Aug 24, 2023

Vicore Pharma Holding AB (publ) Announces First Patient Enrolled in COMPANION; a Digital Therapeutic Pivotal Study for Patients with Pulmonary Fibrosis

Vicore Pharma Holding AB (publ) Announces New Data from the IPF Air Trial Further Strengthening the Benefit-Risk Profile of C21

Vicore Pharma Holding AB (publ) Announces the Appointment of Nomination Committee

Vicore Selects New ATRAG as Next Drug Candidate

Vicore Pharma Holding AB (publ) Announces Positive Results for the Pilot Phase of the COMPANION study

Vicore Pharma Holding AB Announces C21 Promotes Vascular Function in Humans

Vicore Pharma Holding AB (Publ) Provides an Update on the Attract-3 Covid-19 Trial

Vicore Pharma Holding AB (publ) Announces Initiation of First-In-Human Trial with the Novel ATRAG C106

Vicore Pharma Holding AB (publ) Amends Primary Endpoint to Accelerate the Phase 3 Trial in COVID-19 Patients

Vicore Launches COMPANION, A Clinical Study Investigating the Benefit of Digital Therapy on Anxiety in Patients with Idiopathic Pulmonary Fibrosis

Vicore Pharma Holding AB (Publ) Announces Plans to Initiate A Clinical Trial with C21 in PAH

Vicore Pharma Holding AB (Publ) Announces Advancing its First New Chemical Entity from the VP03 Program to a First in Human Phase 1 Trial

Vicore Pharma Holding Announces Data from an Interim Analysis of the Phase 2 Proof-of-Concept Study in IPF

Vicore Pharma Holding AB (publ) Starts Dosing of First Covid-19 Patients in the Global Phase 3 Trial ATTRACT-3

No longer forecast to breakeven

High number of new directors

Vicore Pharma Holding AB (publ) Announces FDA Acceptance for Pivotal Phase 3 Trial of C21 in COVID-19

Vicore Pharma Holding AB (Publ) Announces Top Line Data from A Phase Ii Study of Its Oral Angiotensin II Type 2 Receptor (AT2R) Agonist C21 in Patients with Systemic Sclerosis and Raynaud's Phenomenon

Vicore Pharma Holding AB (Publ) Resumes VP02 Production

Vicore Pharma Holding AB (publ) has completed a Follow-on Equity Offering in the amount of SEK 336 million.

Vicore Pharma Holding AB Announces Positive Data from Phase II Study Attract in Patients with Covid-19 Published Online

New 90-day high: €2.82

Vicore Pharma Holding Reports an Expanded Data Analysis to Follow Up the Encouraging Top Line Data from the ATTRACT

Vicore Pharma Holding AB (Publ) Announces Last Patient Last Visit in the Mechanistic Phase II Study with C21 in Systemic Sclerosis

Vicore Pharma Reports Positive Top Line Data from the ATTRACT clinical study in patients with COVID-19

New 90-day low: €1.78

Vicore Pharma Holding AB Recruits the First Patient in the Phase II Proof-Of-Concept Study in Idiopathic Pulmonary Fibrosis

Vicore Pharma Holding AB (publ) to Report Fiscal Year 2020 Final Results on Apr 15, 2021

Vicore Pharma Holding AB (publ) to Report Q2, 2021 Results on Aug 26, 2021

Vicore Pharma Holding AB (Publ) Announces Completion of Patient Enrollment in the Covid-19 Attract Trial

Vicore Pharma Holding AB (publ) Announces Robust Effects of VP01 in Human Idiopathic Pulmonary Fibrosis Lung Tissue

業績と収益の成長予測

アナリストによる今後の成長予測

一株当たり利益成長率予想

将来の株主資本利益率

成長企業の発掘